Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351941 | 0.87 | TLR7 (0.40) | PARK7 | |
| SCHEMBL16649994 | 0.86 | SSTR4 (0.32) | NFE2L2 | |
| SCHEMBL353833 | 0.86 | BRD4 (0.38) | BRD4BRPF1ALDH1A1PARK7GPR6 | |
| SCHEMBL351825 | 0.83 | PARK7 (0.48) | BRD4BRPF1CTSAHCRTR1KDM4E | |
| SCHEMBL352373 | 0.81 | EGLN1 (0.40) | PARK7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL351942 | 0.79 | PARK7 (0.45) | PARK7 | |
| SCHEMBL168258 | 0.72 | KLKB1 (0.39) | ALDH1A1PARK7MEN1NPC1TP53 | |
| Trifluoroacetic Acid SCHEMBL353832 | 0.69 | PARK7 (0.45) | BRD4BRPF1KDM4EALDH1A1PARK7 | |
| SCHEMBL351903 | 0.68 | PARK7 (0.45) | BRD4BRPF1KDM4EALDH1A1PARK7 | |
| SCHEMBL354624 | 0.67 | PARK7 (0.41) | KDM4EALDH1A1PARK7MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | BRD4 1058/4885BRPF1 2485/4885CTSA 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.